Docket Number:12A-1001018
Inventor:Yuh-Shan Jou, Chia-Yuan Chang
IP Status:Issued TW I445823 、US pending
Abstract:
We applied integrated genomic approaches to reveal novel LMCD1 mutations in HCC. The mutant LMCD1 E135K或K237R can enhance cell migration thru activation of Rac1 signaling pathway. In addition, LMCD1 E135K mutant also promote cancer cell metastasis in nude mice model. Recently, we also discovered the same LMCD1 E135K mutation in nasopharyngeal carcinoma samples. Our results suggested that LMCD1 mutants is a metastatic oncogene in HCC.
Fields of Application:
- Tumor metastasis is the major cause of cancer patient mortality. We identified the metastatic oncogene LMCD1 mutations could allow mono- or combination treatments with conventional cancer therapies to improve therapeutic efficacy.
- Mutant LMCD1 could be a biomarker of tumor metastasis and therapeutic targets. Since LMCD1 mutation activated RAC1 signaling pathway, combined treatments thru inhibition of Rac1 activation pathway is a possible strategy。
- LMCD1 mutations could be the biomarker and target for other cancer types.
Advantages when compared to the existing technologies:
- We identified 6.25% mutation frequency of LMCD1 E135K mutant in HCC patients. It is the first metastatic oncogene identified in HCC. Inhibition of LMCD1 over-expression and its down-stream signaling pathway is an important strategy for therapy.
- With recent advances of surgical operation, radiation and chemotherapies, the outcome of cancer patients remain poor. Our discovery provides a new mono- or combined therapy to simultaneously target tumorigenesis and metastasis.
- Mutant LMCD1 and down-stream alteration to enhanced tumor metastasis could be a biomarker for tumor metastasis and therapeutic target.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
